Journal ArticleOPEN ACCESS

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease

  • Haeberlein S
  • von Hehn C
  • Tian Y
  • et al.
Alzheimer's & Dementia (2020) 16(S9)
DOI: 10.1002/alz.047259
N/ACitations
Citations of this article
84Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Aducanumab is a human monoclonal antibody that selectively targets

Cite

CITATION STYLE

APA

Haeberlein, S. B., von Hehn, C., Tian, Y., Chalkias, S., Muralidharan, K. K., Chen, T., … Sandrock, A. (2020). Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease. Alzheimer’s & Dementia, 16(S9). https://doi.org/10.1002/alz.047259

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free